Distinct Patterns of Myeloid Cell Infiltration in Patients With hrHPV-Positive and hrHPV-Negative Penile Squamous Cell Carcinoma: The Importance of Assessing Myeloid Cell Densities Within the Spatial Context of the Tumor

Tynisha S. Rafael¹, Hielke M. de Vries¹, Sarah R. Ottenhof¹, Ingrid Hofland², Annegien Broeks², Jeroen de Jong³, Elise Bekers⁴, Simon Horenblas¹, Renée X. de Menezes⁵, Ekaterina S. Jordanova¹,⁶*, and Oscar R. Brouwer¹†

¹ Department of Urology, Netherlands Cancer Institute, Amsterdam, Netherlands, ² Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, Netherlands, ³ Department of Pathology, Reini Haga Medisch Diagnostisch Centrum (MDC), The Hague, Netherlands, ⁴ Department of Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands, ⁵ Biostatistics Center, Netherlands Cancer Institute, Amsterdam, Netherlands, ⁶ Center for Gynecologic Oncology Amsterdam (CGOA), Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands

Comprehensive analysis of tumor infiltrating myeloid cells in the tumor microenvironment of penile squamous cell carcinoma (PSCC) is lacking. In this retrospective study, for the first time, PSCC resection specimens (N = 103) were annotated into the following compartments: intratumoral tumor (IT Tumor), intratumoral stroma (IT Stroma), peritumoral tumor (PT Tumor) and peritumoral stroma (PT Stroma) compartments. We then quantified CD14+, CD68+ and CD163+ myeloid cells within these compartments using an image analysis software and assessed their association with various clinical parameters, including high-risk human papillomavirus (hrHPV) status. In the total cohort, hrHPV status, grade of differentiation, age and tumor size were associated with myeloid cell densities. hrHPV+ tumors had higher infiltration rates of CD14+, CD68+ and CD163+ myeloid cells in the IT tumor compartment (p < 0.001, for all) compared to hrHPV− tumors. Furthermore, when examining the association between compartment-specific infiltration and differentiation grade, increased myeloid cell densities in the IT tumor compartment were associated with a more advanced histological grade (p < 0.001, for all). This association remained significant when the hrHPV− cohort (N = 60) was analyzed (CD14+ p = 0.001; CD68+ p < 0.001; CD163+ p = 0.004). Subgroup analysis in the hrHPV− group (N = 43) showed that high infiltration rates of CD68+ and CD163+ cells in the PT tumor compartment were associated with lymph node (LN) metastasis (p = 0.031 and p = 0.026, respectively). Regarding the association between myeloid cell densities and disease-specific survival, the risk of death was found to decrease slightly as the
INTRODUCTION

Penile squamous cell carcinoma (PSCC) is a rare malignancy in developed countries (1, 2). However, the incidence of this mutilating disease is steadily rising in Asian, African and Latin American countries, accounting for up to 10% of malignancies in men (2–4). The prognosis for patients with early stage PSCC is good but worsens with the presence and extent of lymph node metastases (5). Patients with advanced disease have limited treatment options and current cisplatin-based chemotherapy regimens offer poor and non-durable response rates with high toxicity (6, 7). Therefore, there is an unmet need for novel systemic therapeutic strategies that are both effective and tolerable (7).

One of the recognized risk factors of PSCC is a persistent infection with high-risk human papillomavirus (hrHPV), which accounts for 25-40% of all cases (8–11). Importantly, hrHPV−positive (hrHPV−) patients tend to have better disease-specific survival (DSS) than hrHPV−negative (hrHPV−) PSCC patients (8, 9, 11, 12). The exact molecular background of the observed survival differences is unclear. Recent studies have showed that hrHPV+ and hrHPV− tumors are molecularly distinct tumors with different frequency of somatic mutations in p53 pathway genes (13–15). hrHPV+ tumors also constitutively express viral oncoproteins E6 and E7 that deregulate the cell cycle (16). As both genomic alterations and HPV-oncogene expression are known to sculpt the tumor microenvironment, the hrHPV−induced survival advantage might be explained by genetic-induced differences in immune reactivity (17, 18).

Tumors can be highly infiltrated with myeloid cells such as plasmacytoid dendritic cells (pDCs), conventional dendritic cells (cDCs), granulocytes, monocytes and macrophages, all of which have multifaceted functions and influence on disease course and ultimately, patient survival (19, 20). Monocytes are usually classified based on the expression of CD14 and CD16 into classical CD14+CD16− and non-classical CD14+CD16hi monocytes (21, 22). Macrophages are categorized into the pro-inflammatory M1 phenotype (CD68+CD80+) and an immunosuppressive M2 (CD68+CD163+) phenotype based on an in vitro polarization system (21, 23, 24). However, it should be noted that monocyte/macrophage exhibit extraordinary plasticity in vivo and have complex phenotype in the tumor microenvironment beyond this simple categorization (21).

In PSCC, comprehensive analysis of myeloid cell infiltrate is lacking; only limited and conflicting data is available on myeloid cell infiltration (25–27). Several recent studies have highlighted the importance of quantifying immune cell populations within the tissue's spatial context to properly study the impact of immune infiltrates on tumor progression and, ultimately, clinical outcome (28–31). It has been shown that immune cell populations were not randomly distributed within the tumor microenvironment but were either located in the tumor core and/or near the tumor/stroma border (32–34). Moreover, prognostic and predictive value of immune cells may differ dependent on their location within the tumor. In oropharyngeal carcinomas, for example, compartment-specific myeloid densities were shown to be associated with differing clinical outcome (17, 35, 36).

In this hypothesis-generating study, for the first time, penile squamous cell carcinomas resection specimens tissue structure was annotated into several spatial compartments: intratumoral tumor-, intratumoral stroma-, peritumoral tumor- and peritumoral stroma. We then quantified CD14+, CD68+ and CD163+ myeloid cells within the tissue's spatial context using an image analysis software and assessed their association with various clinical parameters, including HPV status and patient survival.

MATERIALS AND METHODS

Study Population and Clinical Data Collection

This retrospective study is based on a previously described cohort of patients who were surgically treated for penile carcinoma between 2001 and 2009 at the Netherlands Cancer Institute, Amsterdam, the Netherlands (8, 27, 37). The original cohort consisted of 213 patients of which 52 were hrHPV+ and 158 were hrHPV−. The hrHPV− patients were chosen to profile the original hrHPV+ cohort based on primary tumor pathological T-stage and cause of death. Forty-three hrHPV+ cases and 60 hrHPV− cases were selected for further image analysis based on the following inclusion criteria: (1) histologically confirmed diagnosis of invasive penile carcinoma, (2) sufficient and adequate material for tissue image analysis. Clinicopathological characteristics of patients (age, HPV status, primary tumor size, grade of...
differentiation, staging and presence of lymphovascular invasion (LVI)) were kept in our institutional penile cancer database. Follow-up data providing information on node positivity, disease status and disease-specific mortality were updated from patient medical records. The institutional translational review board approved the acquisition of tissue material.

**hrHPV-Typing**

hrHPV status was determined on tissue samples using GP5+/6+ PCR enzyme immunoassay for 14 different HPV subtypes (8). The cocktail contained the following hrHPV subtypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.

**Immunohistochemistry**

Immunohistochemical staining was performed with an automated Ventana Benchmark Ultra autostainer (Ventana Medical Systems, Tucson, AZ, USA). FFPE tissue sections (3 μm) were deparaffinized using the EZ prep solution (Ventana Medical Systems) at 75°C. Next, heat-induced antigen retrieval was carried out using Cell Conditioning 1 (CC1, Ventana Medical Systems) for 64 minutes at 95°C. Slides were then incubated at room temperature for 32 minutes with CD14 (ready-to-use, IgG, EPR3653, Ventana Medical Systems), CD68 (1/20000, IgG1, KP1, DAKO), and CD163 (ready-to-use, IgG1, MRQ-26, Cell Marque). Bound antibody was detected using the UltraView DAB Detection kit (CD163, CD14) or the OptiView DAB Detection Kit (CD68) (Ventana Medical Systems). Slides were finally counterstained with Hematoxylin II and Bluing Reagent (Ventana Medical Systems).

**Image Acquisition and Analysis**

Whole-section scans were made using an Aperio Scanner (Leica Biosystems, Solms, Germany). Quantitative analysis of myeloid infiltrates in penile carcinoma were performed (using TissueStudio®; Definiens AG, Munich, Germany) and comprised of several steps. First, the original image files (*.svs) were loaded and representative intratumoral (IT) and peritumoral (PT) regions of interest (ROIs) were manually selected for each patient. In the next step, trained observers annotated stroma, tumor epithelium and tissue structures not deemed for image analysis, such as necrotic areas and/or areas containing tissue- and/or staining- artifacts. The composer’s machine-learning supervised algorithm then classified the tissue accordingly based on inclusion and exclusion annotations. Next, automatic cell segmentation was performed using a hematoxylin and an IHC (3,3′-Diaminobenzidine) marker threshold to accurately locate and segment cells. The final step was to set the threshold for mean brown chromogen which allowed for the distinguishing of positive from negative cells. The exported results contained the final density for each immune marker (number of positive cells per mm²) in the following spatial compartments: peritumoral stroma (PT Stroma), peritumoral tumor epithelium (PT Tumor), intratumoral stroma (IT Stroma) and intratumoral tumor epithelium (IT Tumor). From these data, the final cell densities for the following compartments were calculated: peritumoral (PT Stroma and PT Tumor), intratumoral (IT Stroma and IT Tumor), stroma (PT Stroma and IT Stroma), Tumor (PT Tumor and IT Tumor) and Total (PT Stroma, PT Tumor, IT Stroma and IT Tumor).

**Statistics**

Differences in distribution patterns among compartments were studied using Wilcoxon signed-rank test. Correlation between different immune parameters were assessed using spearman correlation analysis using the ggcourplot R package. Myeloid cell densities were studied in relation to different clinical parameters, including HPV, lymph node metastasis, T-stage, primary tumor size, grade of differentiation and LVI. The normality of the distributions of continuous variables were examined using the Shapiro-Wilk test and qplot. Comparisons between groups were performed using the Chi-square test for the categorical variables and Mann-Whitney U test or the Kruskal-Wallis test for continuous variables. Hierarchical clustering analysis was applied based on row-normalized z-scores of myeloid marker densities with the help of the complexclustermap R package, using spearman correlation as distance metric and complete-linkage as agglomeration method (38). To study the time to event (DSS) and event type probability, a Fine & Gray survival model taking into account competing risks was used, and for this the R package cmprsk was employed (39). All statistical analyses were performed using R (version 4.0.2, Vienna, Austria) and SPSS (version 24, SPSS Inc., Chicago, IL). In all analyses, tests were considered significant for p-values < 0.05. Other details, if any, for each experiment are provided within the relevant figure legends.

**RESULTS**

**Patient and Clinical Characteristics**

The clinicopathological characteristics of the 103 patients stratified by hrHPV status are summarized in Table 1. Of these, 43 (33%) were positive for hrHPV+ and 60 (58%) were hrHPV−. When comparing the hrHPV subgroups with respect to clinical characteristics, we observed a significant difference in grade of differentiation (p = 0.014). Interestingly, even though hrHPV− tumors were mostly grade 1 tumors (43% vs 16%), hrHPV− patients had worse DSS than hrHPV+ counterparts, with 11 (18%) and 1 (2%) PSCC related deaths, respectively (p = 0.038). Among hrHPV+ tumors, HPV16 was the predominant type, followed by HPV18.

**Differential Distribution of Myeloid Cell Populations Across Stroma- and Tumor Compartments**

Representative examples of the immunohistochemical staining results are shown in Figure 1. In order to detect potential differences in infiltration rates in PSCC, CD14+ (Figure 1A), CD68+ (Figure 1B) and CD163+ (Figure 1C) cell populations were quantified and compared between the following spatial compartments: intratumoral tumor (IT Tumor), intratumoral stroma (IT Stroma), peritumoral tumor (PT Tumor) and peritumoral stroma (PT Stroma) (Figures 1D-I).
Myeloid cell densities differed between spatial compartments, with stromal compartments containing higher numbers of CD14+, CD68+ and CD163+ cells than the tumoral compartments (Figure 2A). Further compartmentalization showed similar results; myeloid cell populations displayed the highest density in the PT Stroma and IT Stroma compartments. Comparing the myeloid cell populations, lower number of CD68+ cells were found compared to CD14+ and CD163+ in the stroma compartment (median of cells/mm² 311.4, 1047.1, and 1163.6, respectively), whereas densities in the tumor compartment

### TABLE 1 | Patient characteristics and clinical parameters of the cohort stratified according to hrHPV status.

|                      | Total N = 103 (%) | hrHPV− N = 60 (%) | hrHPV+ N = 43 (%) | p-Value* |
|----------------------|------------------|------------------|------------------|---------|
| Age median (IQR)     | 66.9 (57.2-74.4) | 69.3 (58.8-74.6) | 63.6 (54.4-71.2) | 0.074   |
| Tumor size median (IQR) | 3.0 (1.9-4.0) | 3.0 (2.0-4.5) | 2.5 (1.5-4.0) | 0.240   |
| **pT-stage**         |                  |                  |                  | 0.810   |
| pT1a-b               | 30 (29.1)        | 16 (26.7)        | 14 (32.6)        |         |
| pT2                  | 63 (61.2)        | 38 (63.3)        | 25 (56.1)        |         |
| pT3-4                | 10 (9.7)         | 6 (10.0)         | 4 (9.3)          |         |

**Grade of differentiation**

| Grade | Total N = 103 (%) | hrHPV− N = 60 (%) | hrHPV+ N = 43 (%) | p-Value* |
|-------|------------------|------------------|------------------|---------|
| Grade 1 | 33 (32.0)        | 26 (43.3)        | 7 (16.3)         |         |
| Grade 2 | 52 (50.5)        | 26 (43.3)        | 26 (60.5)        |         |
| Grade 3 | 18 (17.5)        | 8 (13.3)         | 10 (23.3)        |         |
| LVI     | 14 (13.6)        | 8 (13.3)         | 6 (14.0)         | 0.928   |
| pN-stage 1 to 3 | 35 (34.0) | 21 (35.0)        | 14 (32.6)        | 0.796   |
| Death by penis cancer | 12 (11.7) | 11 (18)         | 1 (2)            | 0.038†  |

IQR, interquartile range; hrHPV, high risk human papilloma virus; LVI, lymphovascular invasion; pN-stage, pathological nodal stage.

*Comparing the two hrHPV subgroups. Chi-square test or Fisher’s exact test for the categorical variables and Mann–Whitney U test for the continuous variables.

†Competing risk survival model.

Bold numbers are statistically significant.
FIGURE 2 | (A) Infiltration rates of CD14+, CD68+, and CD163+ cells (cells/mm²) in stromal versus tumoral compartments in PSCC. Myeloid densities in the stromal and tumoral compartments were compared using Wilcoxon-Signed Rank Test, ***p < 0.001. (B) Infiltration rates of CD14+, CD68+, CD163+ (cells/mm²) within the stromal and tumor compartment. (C) Correlation matrix of myeloid cell populations measured in spatial compartments. Blank spaces indicate no significant coefficients and colors correspond to the direction of the correlation (red for positive, blue for negative). Rectangle indicates weak to moderate correlations between densities of CD68+ cells and CD14+ and CD163+ cells in the stromal compartments.
Density and Spatial Distribution of CD14+, CD68+, CD163+ Myeloid Cells in PSCC: Association With Clinicopathological Parameters

We performed unsupervised hierarchical clustering of 90 samples to explore myeloid marker profiles and their association with clinicopathological features (Figure 3). Thirteen patients were excluded from clustering analysis due to missing values. Some patients displayed increased CD14+, CD68+ and CD163+ infiltration rates in the stromal compartments but not in the tumoral compartments, while the opposite was observed for others. These differences in infiltration rates between samples, however, could not be explained by clinicopathological parameters, as samples did not cluster according to clinical features. Further in-depth myeloid infiltration analysis was then performed to determine the associations between compartment-specific CD14+, CD68+ and CD163+ cell densities and clinical parameters.

Interestingly, the hrHPV+ tumors had a markedly different myeloid cell infiltration profile compared to the hrHPV− tumors. The density of CD14+, CD68+, CD163+ cells in the intratumoral tumor (IT Tumor) compartment was significantly higher in hrHPV+ tumors than in hrHPV− tumors (p < 0.001, p < 0.001, p < 0.001, respectively) (Figure 4 and Supplementary Table 1). This correlation, however, was not apparent in the intratumoral stroma (IT Stroma) compartment (p = 0.57, p = 0.08, p = 0.68, respectively). Further compartmentalization of the peritumoral (PT) compartment into PT Tumor and PT Stroma, showed that CD14+ and CD68+ cell densities differed significantly between hrHPV subgroups only when the PT Tumor compartment was taken into account, with increased numbers in the hrHPV+ subgroup (p = 0.004, p = 0.026, respectively) (Figures 4A, B). Overall, differences in myeloid cell densities between hrHPV+ and hrHPV− tumors were found to be mainly driven by the IT Tumor compartment and to some degree by the PT Tumor compartment.

Significant differences were found between hrHPV+ and hrHPV− subgroups in terms of grade of differentiation and myeloid infiltration, with the hrHPV− counterparts having more grade 1 tumors and reduced myeloid cell infiltration in the tumoral compartments. In addition, myeloid cell densities in the tumor compartment were found to differ significantly based
on differentiation grade (CD14 $p = 0.001$; CD68 $p < 0.001$; CD163 $p < 0.001$) (Figure 5 and Supplementary Table 1). Further compartmentalization of the tumor compartment into PT Tumor (CD14 $p = 0.001$; CD68 $p < 0.001$; CD163 $p < 0.001$) and IT Tumor (CD14 $p < 0.001$; CD68 $p < 0.001$; CD163 $p < 0.001$) showed similar results. The prevalence of CD14+, CD68+ and CD163+ cells was higher in grade 3 tumors than in grade 1 tumors, both in PT Tumor and IT Tumor compartments. CD163+ cell numbers also differed significantly between grade 2 and grade 3 tumors, with the latter having increased myeloid cell infiltration in the Tumor, PT Tumor and IT Tumor compartments.

In addition, weak and moderate correlations were found between stromal compartment-specific infiltration rates and clinical parameters, including age and tumor size (Supplementary Table 1). No associations were found between myeloid cell densities...
and lymph node status, T-stage and LVI in the whole cohort (Supplementary Table 1).

Subgroup Analyses

We also investigated the associations between myeloid marker densities and clinicopathological parameters separately across hrHPV− and hrHPV+ subgroups.

In hrHPV− (N = 60), myeloid densities in the tumoral compartments were associated with grade of differentiation. CD14+, CD68+ and CD163+ cell densities in the intratumoral tumor (IT tumor) compartment (p = 0.001; p < 0.001 and p = 0.004, respectively) and peritumoral tumor (PT Tumor) compartment (p = 0.001; p = 0.003 and p < 0.001, respectively) differed between grades of differentiation. Interestingly, in the hrHPV+ subgroup (N = 43) high infiltration rates of CD68+ and CD163+ cells in the PT Tumor compartment were associated with LN metastasis (p = 0.031 and p = 0.026, respectively). High infiltration rates of CD163+ cells in the PT tumor compartment were also associated with grades of differentiation (p = 0.021) and tumor stage (p = 0.030).

Prognostic Significance of CD14+, CD68+ and CD163+ Infiltrating Cells in PSCC

Patients included in this cohort had an average age of 67 years and a large majority (37%) died due to causes not related to penile cancer. Therefore, we performed a survival data analysis to estimate the cumulative incidence function of the event (DSS), allowing for competing risks; that is, we consider as main event death due to penile cancer while correcting for death due to other causes. The survival models were fitted with and without hrHPV status, which is one of the most important clinical prognostic factors for PSCC. For a reference, we also fitted the model of survival with hrHPV status; hrHPV status had a significant positive effect on survival (sHR: 0.12, 95% CI [0.02–0.89], p = 0.038).

We next determined the association between myeloid marker compartment-specific densities (analyzed as continuous variables) and survival in the whole cohort consisting of both hrHPV− and hrHPV+ patients. (Table 2). Although myeloid cell densities in the total compartment were not associated with survival (CD14 p = 0.51; CD68 p = 0.30; CD163 p = 0.13), when
analyzed according to localization, the prognostic value of CD14+, CD68+ and CD163+ could be appreciated. The risk of death was found to decrease slightly but in a statistically significant manner as the number of CD14+ (sHR: 0.997, 95% CI [0.993-1], p = 0.04), CD68+ (sHR: 0.995, 95% CI [0.991-1], p = 0.05) and CD163+ (sHR: 0.995, 95% CI [0.991-1], p = 0.02) myeloid cells in the intratumoral tumor (IT Tumor) compartment. However, after adjusting for hrHPV status, myeloid marker densities in the IT Tumor compartment were no longer significantly associated with survival (CD14 p = 0.65, CD68 p = 0.96, CD163 p = 0.53).

Subgroup Analyses

These analyses were repeated in the hrHPV− subgroup (N = 60) and no associations were found between myeloid marker densities, compartmentalization and survival (Supplementary Table 2).

In the hrHPV+ subgroup (N = 43), only one hrHPV+ patient died due to penile cancer making it impossible to perform meaningful risk analysis in this cohort.

**DISCUSSION**

Current immunotherapy trials are aimed at combating tumor-promoting myeloid cells which, in many tumor types, are key contributors to the tumor microenvironment composition. These tumor-promoting myeloid cells sustain an immunosuppressive environment forming roadblocks for current cancer therapies, including checkpoint inhibitors (40). Patient selection based on the type and infiltration rate of tumor residing myeloid cells may therefore lead to improved response to immunotherapy (19).

With the advancing immunotherapeutic options in mind, our group has extensively studied the tumor microenvironment in hrHPV+ and hrHPV− tumors PSCC over the past decade (8, 27, 37, 41, 42). We and others have shown that hrHPV+ and hrHPV− PSCC tumors are two immunologically distinct subgroups with different levels of immune cell infiltration and immunosuppression (25–27, 37, 43). An increased tumoral PD-L1 immune-checkpoint expression was observed in hrHPV− compared to hrHPV+ tumors (49% versus 32%; P = 0.03) (27, 37). Furthermore, higher density of stromal cytotoxic T cells and stromal granzyme B were observed in HPV+ cases compared to HPV− (25, 26, 43). This observation, however, was not apparent in our previous study (27). Regarding myeloid cells, only a few studies have investigated myeloid cell infiltrates in penile cancer and no differences in myeloid numbers were found between hrHPV+ and hrHPV− cases (25–27). However, these studies only quantified myeloid cells within the tumor and stroma compartments without distinguishing the specific location within the tumor (e.g., tumor nest or periphery).

The compartmentalization of the tumor tissue is of importance when studying the impact of immune cell infiltration on disease pathology, progression and treatment response (29, 30). To our knowledge, this is the first study in penile cancer that reports on the distribution patterns of tumor infiltrating myeloid cells and the associations between compartment-specific myeloid cell densities and clinical parameters. Ultimately, a comprehensive analysis and understanding of tumor-promoting myeloid cells within their spatial context may lead to novel immunotherapeutic strategies in PSCC.

In the present hypothesis-generating study, significant differences were observed between hrHPV+ and hrHPV− tumors, when assessing myeloid cell populations within their spatial context. hrHPV+ tumors had markedly higher numbers of CD14+, CD68+ and CD163+ myeloid cells in the intratumoral tumor (IT Tumor) compartment compared to hrHPV− tumors (p=0.001, p < 0.001, p=0.002, respectively). This observation, however, is not unique for penile cancer. Higher densities of CD68+ and CD163+ cells were also observed in HPV+ tumors of other HPV-induced squamous cell carcinomas, such as oropharyngeal squamous cell carcinoma and cervical squamous cell carcinoma (17, 36, 44, 45). These findings could have important implications for the design of effective

---

**TABLE 2 | The Fine and Gray proportional subdistribution hazard models for penile cancer-specific death in the whole cohort.**

| Single-covariate model | CD14 | CD68 | CD163 |
|------------------------|------|------|-------|
| **sHR** [CI] | p-Value | sHR [CI] | p-Value | sHR [CI] | p-Value |
| Total | 0.999 [0.996-1] | 0.51 | 0.999 [0.996-1] | 0.3 | 0.998 [0.996-1] | 0.13 |
| Tumor | 0.999 [0.996-1] | 0.5 | 0.999 [0.995-1] | 0.18 | 0.999 [0.997-1] | 0.35 |
| Stroma | 1 [0.999-1] | 0.84 | 1 [0.999-1] | 0.53 | 0.999 [0.996-1] | 0.4 |
| IT | 0.997 [0.994-1] | 0.027 | 0.997 [0.993-1] | 0.11 | 0.997 [0.993-1] | 0.068 |
| PT | 1 [0.998-1] | 0.77 | 1 [0.998-1] | 0.91 | 0.999 [0.997-1] | 0.53 |
| IT Tumor | 0.997 [0.993-1] | 0.04 | 0.995 [0.991-1] | 0.05 | 0.995 [0.991-1] | 0.022 |
| IT Stroma | 0.999 [0.998-1] | 0.38 | 1 [0.999-1] | 0.49 | 1 [0.998-1] | 0.84 |
| PT Tumor | 1 [0.997-1] | 0.83 | 1 [0.997-1] | 0.99 | 1 [0.999-1] | 0.32 |
| PT Stroma | 1 [0.999-1] | 0.98 | 1 [0.999-1] | 0.59 | 0.999 [0.998-1] | 0.43 |
| **Multiple covariates model** | | | |
| IT Tumor | 0.999 [0.996-1.00] | 0.65 | 1 [0.994-1.01] | 0.96 | 0.998 [0.993-1.00] | 0.53 |
| hrHPV status | 0.145 [0.016-135] | 0.09 | 0.12 [0.009-1.62] | 0.14 | 0.16 [0.018-1.42] | 0.10 |

*Subdistribution hazard ratio for each point increase in myeloid-cell counts.
Bold numbers are statistically significant.

*IT*, intratumoral; *PT*, peritumoral; *sHR*, subdistribution hazard ratio; CI, 95% confidence interval; hrHPV, high-risk human papilloma virus; LN, lymph node.
The subdistribution hazard model of the Fine and Gray method was used for single-covariate and multiple-covariate analysis of penile cancer-specific death. The subdistribution hazard ratios (sHRs) obtained from the models describe the effect of covariates on the incidence of penile-cancer death after accounting for competing events.
immunotherapeutic strategies, as immune lineages that are different between disease entities may require specific targeting (46). Since hrHPV+ patients had high numbers of tumor-infiltrating myeloid cells and presumably a predominance of the immunosuppressive CD68+CD163+ M2 phenotype, they may require a combination of myeloid cell modulator and an inhibitor of PD-1/PD-L1 axis to overcome the influence of immunosuppressive cells and ultimately enhance anti-tumor response (47–49). Furthermore, hrHPV+ patients with aggressive tumors, may benefit from such combinatorial therapy, as we showed a probable association between high infiltration rates of CD68+ and CD163+ cells in the peritumoral tumor (PT Tumor) and lymph node metastasis. Because lymph node metastasis is the major cause for penile cancer-related deaths, we considered that CD163+ macrophages may have a clinical significance as a prognostic factor in patients with hrHPV+ PSCC. However, here we failed to show a link between CD163+ myeloid infiltration rates and survival in the hrHPV+ subgroup, probably due to the low sample size (N=43) and event rate.

Presently, it is not clear what causes such distinct patterns of myeloid cell infiltration between hrHPV+ and hrHPV− tumors. Emerging evidence suggests that genomic alterations supporting the development of cancer can dictate the immune contexture of tumors (50). In line with the above, we hypothesized that significant differences in myeloid cell numbers may be related to the two distinct etiologies of PSCC: the hrHPV-dependent and hrHPV-independent carcinogenesis. Moreover, growing efforts to identify genomic alterations implicated in the two pathways of PSCC development have expanded our knowledge on mutational patterns. Recent studies have shown that the frequency of mutations was mostly similar between HPV+ and HPV− PSCC, with some exceptions, such as mutations in p53 pathway genes (P53, CHECK2, CDKN2A), which were commonly mutated in HPV− but not in HPV+ PSCC (13, 14). Similar to PSCC, HPV− vulvar and head and neck cancers exhibit lower frequency of TP53 mutations than HPV+ tumors (13, 14, 51–56). This owes mainly to the action of E6 in eliminating p53 leaving HPV+ cancer cells with less evolutionary pressure to select for p53 mutations (57). Moreover, in several tumor models, loss or loss-of-function mutation of p53 activated the NF-kB pathway, changing the secretome of cancer cells and thereby modulating the tumor microenvironment by recruiting monocytes and macrophages (50). In hrHPV+ PSCC, loss of p53 may also prolong NF-kB activation and consequently change the secretome of HPV+ cancer cells, inducing the chemokine-dependent recruitment of macrophages and/or polarization of macrophages toward a tumor-promoting CD68+CD163+ M2 phenotype. Further research in a larger cohort is needed to study the mutational landscape of hrHPV+ and hrHPV− PSCC and to determine how mutational signatures can influence the secretome and consequently the myeloid component of these tumors. Furthermore, from a clinical perspective, better insights into what drives myeloid cell infiltration can help identify novel targets for anti-cancer immunomodulatory therapies.

Myeloid cell infiltration patterns were also associated with grade of differentiation, with higher myeloid cell infiltration rates found in tumors with a more advanced histological grade. This has been previously described in oropharyngeal, bladder and triple negative breast cancers, but the underlying mechanism is still unknown (58–61). The association between myeloid infiltration patterns and grade of differentiation remained significant when the hrHPV+ subgroup was analyzed separately. These findings raise the question whether hrHPV+ tumors were weakly infiltrated compared to hrHPV− tumors because they were mostly grade 1 tumors or that they were mostly grade 1 tumors because of the less extensive myeloid infiltration. The latter suggests a potential role of myeloid cells in tumor progression. In cervical and oropharyngeal cancer, for example, high infiltration by CD163+ and CD68+ macrophages was correlated with the tumor progression from normal tissue to dysplasia to carcinoma (45, 49). Additional studies are needed to investigate whether myeloid cells can serve as potential marker for disease progression and elucidate the potential mechanism by which myeloid cell infiltration patterns promote penile cancer progression.

Next, competing risk models were performed to study the association between myeloid cell densities, compartmentalization and survival. When CD14+, CD68+ and CD163+ myeloid densities in the intratumoral tumor (IT Tumor) increased, the risk of death was found to decrease slightly but in a statistically significant manner. However, no significant associations were found between myeloid densities and survival after adjusting for hrHPV status. This could be explained by the fact that hrHPV+ patients had a more favorable survival than hrHPV− counterparts and higher levels of myeloid cell densities in the intratumoral tumor (IT Tumor) compartment. These results were not in accordance with other studies in HPV-induced carcinomas, showing that macrophages number was an independent prognostic factor (44, 62). However, both these studies used cut-off points for creating subgroups for survival analysis and cut-off points are generally data-specific and may not be as reproducible and applicable in a clinical setting as using the continuous data.

A major strength of this study is that myeloid cell infiltration rates were quantified within the spatial context of the tumor using robust image analysis algorithms. However, in addition to determining compartment-specific infiltration, it is important to determine the phenotype of immune cell subpopulations residing in the different tumor compartments. Most studies on myeloid infiltrates have classified myeloid cells into monocytes, tumor associated macrophages (TAMs), tumor-associated granulocytes, myeloid-derived suppressor cells (MDSCs) or monocyt–derived dendritic cells (20, 63). The IHC methodology used here, however, did not allow for the identification of different myeloid cell subsets. Interestingly, we found relatively lower CD68+ myeloid densities in the stromal compartments compared to CD163+ infiltrating cells. One explanation could be that a considerably higher number of single positive CD163+ cells was present in the stromal compartment compared to CD68+CD163+ cells. In OPSCC, for example, higher numbers of single positive CD163+ cells were observed in the stroma compared to double-positive
CD68+CD163+ cells and single positive CD68+ cells (64). Similarly, in the tumor microenvironment of HPV16+ OPSCC patients, CD14–CD33−CD163+ cell populations were found to consist of CD14–CD68+CD163+ M2 macrophages and an underappreciated population of CD14–CD68–CD163+ CD1c+ conventional dendritic cell type 2 (65). These cells produce high levels of IL-12 and IL-18 cytokines, which are required for type 1 T cell responses, and have been correlated with prolonged survival (65). Further characterization of the specific myeloid cell subpopulations in PSCC is needed and a solution to that problem could be the application of high-dimensional techniques, such as multiplex immunofluorescence and/or imaging mass cytometry, that enable simultaneous spatial analysis of multitude of cell types, which is critical for understanding the tumor-immune system cross-talk (66–70). Therefore, our group is currently aiming to comprehensively characterize the tumor microenvironment of hrHPV+ and hrHPV− PSCC tumors using the above-mentioned high-dimensional technologies.

Another limitation of this study is that no correction for multiple testing was applied. We did not perform multiple testing correction to avoid the chance of dramatically increasing the risk of committing type II errors and therefore decreasing the possibility of detecting real differences (71). Since knowledge on the tumor microenvironment in penile cancer is scarce and there is unmet need for new treatment strategies, we believe further confirmatory studies in another cohort are needed to confirm the results of this hypothesis-generating study.

In conclusion, the assessment of myeloid cell densities within their spatial context seems to be essential for identifying immune microenvironment differences between hrHPV+ and hrHPV− PSCC, with the latter having higher CD14+, CD68+ and CD163+ myeloid cell infiltration in the intratumoral tumor (IT Tumor) compartment. Further confirmatory studies are needed to not only validate our results but also to characterize the specific myeloid cell subpopulations residing in the tumoral compartments and understand the impact of HPV on their recruitment in hrHPV+ PSCC. Ultimately, this will lead to better understanding of the tumor microenvironment of this rare tumor type and may help improve selection of PSCC patients for specific myeloid cell-targeting immunotherapy trials.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by NKI translational review board. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

**AUTHOR CONTRIBUTIONS**

This study was designed by EJ, SH, and OB. Image analysis was done by TR and EJ, and revised by EB and JJ. Clinicopathological data were collected by SO and HV, and parts of it were revised by JJ. IH and AB performed immunohistochemistry stainings. Statistical analysis was done by TR and RM. The manuscript was drafted by TR, and sections of it were written by HV, EJ, and OB. All authors contributed to the article and approved the submitted version.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.682030/full#supplementary-material

**REFERENCES**

1. Barnholtz-Sloan JS, Maldonado JL, Pow-Sang J, Guiliano AR. Incidence Trends in Primary Malignant Penile Cancer. *Urol Oncol* (2007) 25:361–7. doi: 10.1016/j.urolonc.2006.08.029
2. Christodoulidou M, Sahdev V, Houssein S, Muneer A. Epidemiology of Penile Cancer. *Curr Probl Cancer* (2015) 39:126–36. doi: 10.1016/j.currprobcancer.2015.03.010
3. Vieira CB, Feitosa L, Pinho J, Teixeira-Juão A, Lages J, Calixto J, et al. Profile of Patients With Penile Cancer in the Region With the Highest Worldwide Incidence. *Sci Rep* (2020) 10:2965. doi: 10.1038/s41598-020-59831-5
4. Coelho RWP, Pinho JD, Moreno JS, Garbis DVEO, do Nascimento AMT, Lorges JS, et al. Finger Lickin’ Good? Penile Cancer in Maranhão, Northeast Brazil: The Highest Incidence Globally? *BMC Urol* (2018) 18:50. doi: 10.1186/s12894-018-0365-0
5. Djajadiningrat RS, Graafland NM, van Werkhoven E, Meinhardt W, Bea A, van der Poel HG, et al. Contemporary Management of Regional Nodes in Penile Cancer—Improvement of Survival? *Int J Cancer* (2015) 131:1–9. doi: 10.1002/ijc.29616
6. Steinek J, Al Ghazal A, Arndt A, Schnoeller TJ, Schrader AJ, Moeller P, et al. The Role of Histologic Subtype, P16 INK4a Expression, and Presence of Human Papillomavirus DNA in Penile Carcinoma Predicts Favorable Outcome in Survival. *Int J Cancer* (2006) 119:1078–81. doi: 10.1002/ijc.21961
7. Thomas A, Necchi A, Muneer A, Tobias-Machado M, Tran A, Van Rompuy A-S, et al. Penile Cancer. *Nat Rev Dis Primers* (2017) 1:7–24. doi: 10.1038/nrdp.2017.024
8. Djajadiningrat RS, Jordanova ES, Kroon BK, van Werkhoven E, de Jong J, Pronk DTM, et al. Human Papillomavirus Prevalence in Invasive Penile Cancer and Association With Clinical Outcome. *J Urol* (2015) 193:526–31. doi: 10.1016/j.juro.2014.08.087
9. Lont AP, Kroon BK, Horenblas S, Gallee MPW, Berkhof J, Meijer CJLM, et al. Presence of High-Risk Human Papillomavirus DNA in Penile Carcinoma. *Adv Exp Med Biol* (2013) 73:31. doi: 10.1007/978-1-4614-4448-5
10. Steinek J, Al Ghazal A, Arndt A, Schnoeller TJ, Schrader AJ, Moeller P, et al. The Role of Histologic Subtype, P16 INK4a Expression, and Presence of Human Papillomavirus DNA in Penile Squamous Cell Carcinoma. *BMC Cancer* (2015) 15:1–9. doi: 10.1186/s12885-015-1268-z
11. Ferrándiz-Pulido C, Maferrer E, De Torres I, Lloveras B, Hernandez-Losa J, Mojal S, et al. Identification and Genotyping of Human Papillomavirus in a Spanish Cohort of Penile Squamous Cell Carcinomas: Correlation With Pathologic Subtypes, p16INK4a Expression, and Prognosis. *J Am Acad Dermatol* (2013) 68:73–82. doi: 10.1016/j.jaad.2012.05.029
12. Sand FL, Rasmussen CL, Frederiksen MH, Andersen KK, Kjaer SK. Prognostic Significance of HPV and P16 Status in Men Diagnosed With Penile Cancer: A Systematic Review and Meta-Analysis. Cancer Epidemiol Prev Biomarkers (2018) 27:1123–32. doi: 10.1158/1055-9966.EPI-18-0322

13. Chahoud J, Pickering CR, Pettaway CA. Genetics and Penile Cancer: Recent Developments and Implications. Curr Opin Urol (2019) 29:364–70. doi: 10.1097/MOU.0000000000000640

14. Chahoud J, Geber-Netto F, McCormick B, Rao P, Lu X, Guo M, et al. Whole Exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma. Clin Cancer Res (2021) 27:2560–70. doi: 10.1158/1078-0432.CCR-20-0041

15. McDaniels AS, Hovelson DH, Cani AK, Liu C-J, Zhai Y, Zhang Y, et al. Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy. Cancer Res (2015) 75:5219 LP – 5227. doi: 10.1158/0008-5472.CAN-15-1004

16. Mittal S, Banks L. Molecular Mechanisms Underlying Human Papillomavirus E6 and E7 Oncoprotein-Induced Cell Transformation. Mutat Res Mutat Res (2017) 772:23–35. doi: 10.1016/j.mrrev.2016.08.001

17. Snietsma M, Brewczynski A, Kopec A, Rutkowski T. Infiltrates of M2-Like Tumour-Associated Macrophages are Adverse Prognostic Factor in Patients With Human Papillomavirus-Negative But Not in Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma. Pathobiology (2020) 87:75–86. doi: 10.1159/000505522

18. Gameiro SF, Ghasemi F, Barrett JW, Koropatnick J, Nichols AC, Mymryk JS, et al. Treatment-Naïve HPV+ Head and Neck Cancers Display a T-cell-infiltrated Phenotype Distinct From Their HPV- Counterparts That Has Implications for Immunotherapy. Oncoimmunology (2017) 8:e1494393–e1494398. doi: 10.1080/2162402X.2018.1498439

19. Awad RM, De Vlaeminck A, Maebe J, Crepek B. K Turn Back the TiM: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression. Front Immunol (2018) 9:1977. doi: 10.3389/fimmu.2018.01977

20. Elliot LA, Doherty GA, Sheahan K, Ryan EJ. Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity. Front Immunol (2017) 8:866. doi: 10.3389/fimmu.2017.00866

21. Cheng S, Li Z, Gao R, Zhai Y, Zhang Y, et al. Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy. Cancer Res (2015) 75:5219 LP – 5227. doi: 10.1158/0008-5472.CAN-15-1004

22. Awad RM, De Vlaeminck A, Maebe J, Goyvaerts C, Breckpot K. Turn Back the TiM: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression. Front Immunol (2018) 9:1977. doi: 10.3389/fimmu.2018.01977

23. Vogel DYS, Glin JE, Stavenuiter AWD, Breur M, Heijnen P, Amor S, et al. Human Macrophage Polarization In Vitro: Maturation and Activation Methods. Immunobiology (2014) 219:695–703. doi: 10.1016/j.imbio.2014.05.002

24. Khramtsova G, Liao C, Khramtsov A, Li S, Gong C, Huo D, et al. The M2/Infiltrating Myeloid Cells to Revert Cancer Progression. Front Immunol (2018) 9:1977. doi: 10.3389/fimmu.2018.01977

25. Onkar S, Wang T, Imperiali D, Tabib T, Qi Z, Kürten CHL, et al. Immune Monitoring of M2-Like Macrophages in HPV+ T Cells in HPV+ and CD68 Macrophages in HPV- Oropharyngeal Squamous Cell Carcinomas are Associated With Better Clinical Outcome But PD-L1 Expression is Not Prognostic. Oncotarget (2017) 8:14416–27. doi: 10.18632/oncotarget.17496

26. Ottenhof SR, Djaadjinagnrat RS, de Jong J, Thyesen HH, Horensblas S, Jordana ES. Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated With HPV Status. J Urol (2017) 197:690–7. doi: 10.1016/j.juro.2016.09.088

27. Gu Z, Eils R, Schlesner M. Complex Heatmaps Reveal Patterns and Correlations in Multidimensional Genomic Data. Bioinformatics (2016) 32:2847–9. doi: 10.1093/bioinformatics/btw313

28. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc (1999) 94:496–509. doi: 10.1080/00031305.1999.1047414

29. Liu Y, Wang R. Immunotherapy Targeting Tumor-Associated Macrophages. Front Med (2020) 7:583708. doi: 10.3389/fmed.2020.583708

30. Djaadjinagnrat RS, Horensblas S, Heideman DAM, Sanders J, de Jong J, Jordana ES. Classic and Nonclassic HLA Class I Expression in Penile Cancer and Relation to HPV Status and Clinical Outcome. J Urol (2015) 193:1245–51. doi: 10.1016/j.juro.2014.11.057

31. de Vries HM, Onthofsr SR, Horensblas S, van der Heijden MS, Jordana ES. Defining the Tumor Microenvironment of Penile Cancer by Means of the Cancer Immune Profiling. Eur Urol Focus (2019) 5:718–21. doi: 10.1016/j.euf.2019.02.019

32. Lohneis P, Boral S, Kaufmann AM, Lehmann A, Schewe C, Dietl M, et al. Human Papillomavirus Status of Penile Squamous Cell Carcinoma is Associated With Differences in Tumour-Infiltrating T Lymphocytes. Virchows Arch (2015) 466:323–31. doi: 10.1007/s00428-014-1713-4

33. Seminario I, Kindt N, Descamps G, Bellier J, Lachjen JM, et al. High Infiltration of CD68+ Macrophages Is Associated With Poor Prognoses of Head and Neck Squamous Cell Carcinoma Patients and is Influenced by Human Papillomavirus. Oncotarget (2018) 9:11046. doi: 10.18632/oncotarget.24306

34. Chen X-J, Han L-F, Wu X-G, Wei W-F, Wu L-Y, Yi H-Y, et al. Clinical Significance of CD163+ and CD68+ Tumor-Associated Macrophages in High-Risk HPV-related Cervical Cancer. J Cancer (2017) 8:3868. doi: 10.7155/jca.21444

35. Cillo AR, Kürten CHL, Tabib T, Qi Z, Onkar S, Wang T, et al. Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer. Immunology (2020) 52:183–99.e9. doi: 10.1111/imm.13563

36. Nakkle J, Pierron V, Bauchet A-L, Plas P, Thiognane A, Meyer-Losic F, et al. Tassquinmod Modulates Tumor-Infiltrating Myeloid Cells and Improves the Antitumor Immune Response to PD-L1 Blockade in Bladder Cancer. Oncoimmunology (2016) 5:e1145333. doi: 10.1080/2162402X.2016.1145333

37. Galliverti G, Wullschleger S, Tichet M, Murugan D, Zangger N, Horton W, et al. Myeloid Cells orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy Against CD68+ Macrophages. Cancer Immunol Res (2020) 8:131–45. doi: 10.1158/2326-6066.ICI-19-0315

38. Lechien JR, Descamps G, Seminario I, Furgiuele S, dequanter D, Mouawad F, et al. HPV Involvement in the Tumor Microenvironment and Immune

Frontiers in Immunology | www.frontiersin.org 12 June 2021 | Volume 12 | Article 682030
Treatment in Head and Neck Squamous Cell Carcinomas. Cancers (Basel) (2020) 12:1060. doi: 10.3390/cancers12051060

50. Wellenstein MD, de Visser KE. Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape. Immunity (2020) 48:399–416. doi: 10.1016/j.immuni.2018.03.004

51. Jacob MJ, Ferry EK, Gay LM, Elvin JA, Vergilio J-A, Ramkissoon S, et al. Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy. J Urol (2019) 201:541–8. doi: 10.1016/j.juro.2018.09.056

52. Trietsch MD, Nooij LS, Gaarenstroom KN, van Poelgeest MIE. Genetic and Comparative Genomic Changes in Vulvar Squamous Cell Carcinoma and its Precursor Lesions: A Review of the Current Literature. Gynecol Oncol (2015) 136:143–57. doi: 10.1016/j.ygyno.2014.11.00

53. Ziáha S, Kowalik A, Zalewski K, Rusetska N, Goryca K, Piasik A, et al. Somatic Mutation Profiling of Vulvar Cancer: Exploring Therapeutic Targets. Gynecol Oncol (2018) 150:552–61. doi: 10.1016/j.ygyno.2018.06.026

54. Network CGA. Comprehensive Genomic Characterization of Head and Neck Squamous Cell Carcinomas. Nature (2015) 517:576. doi: 10.1038/nature14129

55. Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. HPV, Epigenetic Changes in Vulvar Squamous Cell Carcinoma and its Precursor Lesions: A Review of the Current Literature. Gynecol Oncol (2015) 136:143–57. doi: 10.1016/j.ygyno.2014.11.00

56. Hong A, Zhang X, Jones D, Veillard A-S, Zhang M, Martin A, et al. Relationships Between p53 Mutation, HPV Status and Outcome in Oropharyngeal Squamous Cell Carcinoma. Radiother Oncol (2016) 118:342–9. doi: 10.1016/j.radonc.2016.02.009

57. Göttgens E-L, Ostheimer C, Span PN, Bussink J, Hammond EM, HPV, Hypoxia and Radiation Response in Head and Neck Cancer. Br J Radiol (2018) 92:20180047. doi: 10.1259/bjr.20180047

58. Maniecki MB, Etzerodt A, Ulhøi BP, Steiniche T, Borre M, Dyrskjøt L, et al. Tumor-Promoting Macrophages Induce the Expression of the Macrophage-Specific Receptor CD163 in Malignant Cells. Int J Cancer (2012) 131:2320–31. doi: 10.1002/ijc.27506

59. Fortis SP, Sotopoulos M, Sotiriadou NN, Haritos C, Vaxevanis CK, Anastasopoulos EA, et al. Differential Intratumoral Distributions of CD8 and CD163 Immune Cells as Prognostic Biomarkers in Breast Cancer. J Immunother Cancer (2017) 5:39. doi: 10.1186/s40425-017-0240-7

60. Mori K, Hiroi M, Shimada J, Ohmori Y. Infiltration of M2 Tumor-Associated Macrophages in Oral Squamous Cell Carcinoma Correlates With Tumor Malignancy. Cancers (Basel) (2011) 3:3726–39. doi: 10.3390/cancers303726

61. Yamagata Y, Tomioka H, Sakamoto K, Sato K, Harada H, Ikeda T, et al. CD163-Positive Macrophages Within the Tumor Stroma Are Associated With Lymphangiogenesis and Lymph Node Metastasis in Oral Squamous Cell Carcinoma. J Oral Maxillofac Surg (2017) 75:2144–53. doi: 10.1016/j.joms.2017.03.009

62. Lu C-F, Huang C-S, Tjiu J-W, Chiang C-P. Infiltrating Macrophage Count: A Significant Predictor for the Progression and Prognosis of Oral Squamous Cell Carcinomas in Taiwan. Head Neck (2010) 32:18–25. doi: 10.1002/hed.21138

63. Vainnin Y, González-Rascón A, Goyvaerts C, Breckpot K. Cancer-Associated Myeloid Regulatory Cells. Front Immunol (2016) 7:113. doi: 10.3389/fimmu.2016.00113

64. Fortis SP, Sofopoulos M, Sotiriadou NN, Haritos C, Vaxevanis CK, Anastasopoulos EA, et al. A 40-Marker Panel for High Dimensional Characterization of Cancer Immune Microenvironments by Imaging Mass Cytometry. Front Immunol (2019) 10:2534. doi: 10.3389/fimmu.2019.02534

65. Keren L, Bosse M, Marquez D, Angoshiari R, Jain S, Varma S, et al. A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging. Cell (2018) 174:1373–87. doi: 10.1016/j.cell.2018.08.039

66. Ji AL, Rubin AJ, Thrane K, Jiang S, Reynolds DL, Meyers RM, et al. Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma. Cell (2020) 182:497–514.e22. doi: 10.1016/j.cell.2020.05.039

67. Zwing N, Failmezger H, Ooi C-H, Hifar DP, Cañamero M, Gomes B, et al. Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer-a Potential Tool for Discovering Prognostic Biomarkers in Clinical Research. Front Immunol (2020) 11:550250. doi: 10.3389/fimmu.2020.550250

68. Armstrong RA. When to Use the Bonferroni Correction. Ophthalmic Physiol Opt (2014) 34:502–8. doi: 10.1111/opo.12131

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.